Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 14, 2015European Journal of Heart FailureOpen Access

Baseline ET-1 was independently associated with 180-day mortality (HR 1.6, 95% CI 1.3-2.0, P < 0.001, log-transformed).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Are elevated plasma Endothelin-1 levels associated with increased mortality and adverse outcomes in patients hospitalized with acute heart failure?

Population

872 patients hospitalized with acute heart failure from the ASCEND-HF trial

Design

Cohort

Follow-up

180 days

Authors

APAntonio L. PérezJGJustin L. GrodinYWYuping Wu

Discussion

Loading...

Member takes

Overview

ET-1 may refine short-term risk stratification in acute HF; hypothesis-generating and requires prospective validation before clinical use.

Structured PICO

Are elevated plasma Endothelin-1 levels associated with increased mortality and adverse outcomes in patients hospitalized with acute heart failure?

P
Population
872 patients hospitalized with acute heart failure from the ASCEND-HF trial
I
Intervention
Plasma Endothelin-1 (ET-1) levels measured at baseline, 48-72 h, and 30 days
O
Outcome
30-day mortality, 180-day mortality, in-hospital death or worsening heart failure, and 30-day mortality or rehospitalizationhard clinical

Elevated plasma Endothelin-1 levels provide independent prognostic information for short-term and 180-day mortality in acute heart failure, incremental to NT-proBNP.

Cite This Study

Pérez et al. (2015) studied this question.

synapsesocial.com/papers/6a7cd77538ddfc9027febe6bhttps://doi.org/10.1002/ejhf.456
View Full Paper
Ask AI
Bookmark
Share